The Nrf2 inhibitor brusatol synergistically enhances the cytotoxic effect of lapatinib in HER2-positive cancers

The Nrf2 inhibitor brusatol synergistically enhances the cytotoxic effect of lapatinib in HER2-positive cancers

The dual tyrosine kinase (EGFR/HER2) inhibitor lapatinib is currently used to clinically treat HER2-positive breast cancer. However, a majority of patients do not respond to lapatinib therapy within 6 months. Therefore, potentiating the anti-tumor effect of lapatinib by combination treatment has a g...

Full description

Bibliographic Details
Main Authors: Ziyin Tian, Yan Yang, He Wu, Yongye Chen, Hao Jia, Lei Zhu, Runjia He, Yibo Jin, Bei Zhou, Chunpo Ge, Yanxia Sun, Yun Yang
Format: Article
Language:English
Published: Elsevier 2022-08-01
Series:Heliyon
Subjects:
Nrf2
Brusatol
Lapatinib
HER2
ROS
ERK1/2
Online Access:http://www.sciencedirect.com/science/article/pii/S240584402201698X

Internet

http://www.sciencedirect.com/science/article/pii/S240584402201698X

Similar Items